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SYSTEM AND METHOD FOR INTRANASAL 
ADMINISTRATION OF LORAZEPAM 
This Application is a Continuation-in-Part of co-pending 
application Ser. No. 09/569,125, ?led May 10, 2000, noW 
abandoned. 
FIELD OF THE INVENTION 
The invention relates to pharmaceutical drug composi 
tions and preparations of loraZepam. This invention also 
relates to pharmaceutical drug delivery devices, speci?cally 
to devices for the intranasal administration of loraZepam. 
BACKGROUND OF THE INVENTION 
LoraZepam preparations for the treatment of anxiety 
related disorders and to induce sedation have been previ 
ously approved by the US. Food and Drug Administration 
(“FDA”) and have been long-used for oral, intramuscular 
and/or intravenous administration. LoraZepam is currently 
marketed in injectable and tablet formulations. Marketers of 
these preparations have not sought regulatory approval from 
the FDA for liquid compositions of the same therapeutic 
compound for intranasal administration. This is surprising 
since it is Well-knoWn from the literature that the intranasal 
administration of a pharmacologically active compound 
generally results in a more rapid bioavailability of the 
compound, or of its desired active metabolite than if the 
compound is administered orally. Moreover, the time 
required to achieve the same concentration of the active 
compound in the bloodstream e.g., Within a period of about 
thirty minutes after administration, is generally less via the 
intranasal route compared to oral administration. 
It has been reported that, folloWing oral administration, 
peak plasma concentrations of approximately 25 ng/mL 
Were not observed until approximately 2.4 hours after 
administration With a bioavailability of 99.8%. (Greenblat, 
et al., Journal of Pharmaceutical Sciences, Vol. 66, No. 1 
(1979).) It has also been reported that, folloWing intranasal 
administration of loraZepam in a Cremophor EL, a non 
aqueous vehicle, the time to peak plasma concentration Was 
1.4 hours With a bioavailability of 51%. (Lau and Slattery, 
International Journal of Pharmaceuticals, 54 (1989) 
171—174.) 
The intranasal route of administration also provides 
numerous advantages over intravenous (IV) and intramus 
cular (IM) injections. One principal advantage of intranasal 
administration is convenience. An injectable system requires 
steriliZation of the hypodermic syringe and in the institu 
tional setting, leads to concerns among medical personnel 
about the risk of contracting disease if the they are acciden 
tally stuck by a contaminated needle. Strict requirements for 
the safe disposal of the used needle and syringe must also be 
imposed in the institutional setting. In contrast, intranasal 
administration requires little time on the part of the patient 
and the attending medical personnel, and is far less burden 
some on the institution than injectables. There is no signi? 
cant risk of infection of medical personnel or others in the 
institutional setting that is associated With nasal spray 
devices. 
A second important advantage of intranasal administra 
tion over IM and IV is patient acceptance of the drug 
delivery system. Many, if not most, patients experience 
anxiety and exhibit symptoms of stress When faced With 
hypodermic injections via the IM or IV routes. In some 
cases, the after-effects of the injection include burning, 
edema, sWelling, turgidity, hardness and soreness. In 
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contrast, intranasal administration is perceived as non 
invasive, is not accompanied by pain, has no signi?cant 
after-effects and produces the grati?cation of prompt relief 
in the patient exhibiting the symptom. This is of particular 
advantage When the patient is a child. Most people have 
some familiarity With nasal sprays in the form of over-the 
counter decongestants for alleviating the symptoms of colds 
and allergies that they or a family member have used 
routinely. Another important consideration is that the patient 
can self-administer the prescribed dosage(s) of nasal spray. 
An empty nasal spray device, or one containing a non 
medicated solution can be given to the patient to practice the 
technique for proper insertion, inhalation and activation for 
self-administration. 
In vieW of the aforementioned advantages and bene?ts 
afforded by the intranasal administration, it Would be 
expected that a preparation of loraZepam exhibiting systemic 
pharmacological activity Would presently be available for 
intranasal administration. This has not occurred, despite the 
fact that preparations for oral, IM and IV administration 
have been approved for commercial use for many years. 
Despite the remarkable commercial success that has been 
enjoyed by those drugs that have been made available in 
intranasal form, in fact, only a very limited number of 
compounds are commercially available to physicians to 
prescribe and dispense to their patients in that form. 
Furthermore, only one multiple-dose spray device has 
apparently been approved by the FDA for intranasal admin 
istration of an opiate solution that is categoriZed as a 
controlled substance. The devices that are presently avail 
able exhibit several de?ciencies. One spray device intended 
for multiple uses must be primed before use by expelling a 
portion of the liquid contents in order to assure that the pump 
mechanism and delivery tube are ?lled. Up to seven or eight 
activations are required to prime the device. It is also 
indicated that further priming to disperse one or tWo sprays 
is to be performed if the device is not used for 48 hours or 
longer. These procedures necessarily result in the dispenser 
being over?lled in order to assure that there Will be suf?cient 
liquid to deliver the labelled number of doses. It has been 
found that a substantial volume of the controlled substance 
often remains in the device, even after the labelled number 
of doses have been administered. In practice, it has also been 
found that medical personnel and Workers at health care 
facilities routinely abscond With the dispensers, sometimes 
after the patient has had only one or a feW of the prescribed 
doses in a multi-dose container. This improper use of 
controlled substances as so-called “recreational drugs” is 
Well-knoWn among medical facility managers and laW 
enforcement authorities. So far as is presently knoWn, no 
preventative measures have been reported that are effective 
in dealing With this problem. 
A further problem resides in dispensing to a patient 
intranasal spray devices With suf?cient ?uid contents for 
numerous doses for anxiety control purposes. Because a 
patient suffering from a disorder and exhibiting anxiety may 
not act rationally in self-administering a drug for relief of the 
symptom, there is a potential for overdosing. Moreover, 
because of the nature and construction of these multiple dose 
spray devices, medical personnel cannot easily determine 
the number of doses that have been administered by a simple 
visual inspection of the device. 
Another problem that has recently been identi?ed in 
clinical studies is the relative inaccuracy of multi-dose 
intranasal delivery devices that are currently being marketed 
With opiate solutions for the control of pain. Not only does 
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the average volume of liquid spray actually administered fall 
about 10% below the purported dosage appearing on the 
approved label for one such product, signi?cant variations 
Were also observed among a series of administrations by 
each patient in the study group. Thus, spray devices tested 
containing an opiate compound classed as a “controlled 
substance” by the FDA Were found to be capable of admin 
istering only about 90% by volume of the prescribed dosage, 
on average, and the dosage actually received by each patient 
in repeated administrations exhibited substantial signi?cant 
variations of from 60% to 130% of the claimed label dosage. 
OBJECTS OF THE INVENTION 
Accordingly, it is a principal object of the invention to 
provide a novel therapeutic composition of loraZepam and 
its pharmaceutical by acceptable derivatives for intranasal 
administration of at least one predetermined volumetric unit 
dose in the form of a spray by means that delivers one or 
more therapeutically prescribed unit doses that are highly 
accurate as to the volume discharged and Which leave no 
signi?cant quantity of the composition in the delivery 
means. 
Another object of the invention is to provide a novel 
composition comprising loraZepam, a knoWn compound that 
is approved for oral, IM and/or IV administration, for use in 
a highly accurate and reproducible intranasal spray delivery 
system in a single unit-dose or therapeutically prescribed 
multiple unit-dose. 
It is a further object of this invention to provide an 
improved intranasal dosage composition and method of 
administration of loraZepam that exhibits a relatively rapid 
onset, moderate duration of therapeutic activity, minimal 
side effects, improved bioavailability, ease and safety of 
administration, and minimal physical discomfort and anxi 
ety to the patient occasioned by administration. 
It is another object of this invention to provide an intra 
nasal delivery system for one or more unit doses of novel 
therapeutic compositions containing loraZepam that permits 
administration of one or more therapeutically prescribed 
unit-doses in a medical care facility, such as a hospital, day 
clinic, or doctor or dentist’s of?ce in Which the delivery 
system contains essentially no signi?cant quantity of the 
therapeutic composition after administration of the single 
unit-dose or the prescribed number of multiple unit-doses. 
It is also an object of the invention to provide the novel 
and improved combination of a device for intranasal admin 
istration and a formulation for loraZepam that meet the 
requirements for FDA approval. 
Yet another object of the invention is to provide such 
novel loraZepam compositions for intranasal administration 
in a relatively small and inexpensive, manually operated, 
self-contained hand-held disposable device that retains 
essentially no signi?cant quantity of the therapeutic com 
position after administration of the one or more unit-doses as 
prescribed. 
A further object of the invention is to provide a compre 
hensive method for providing a novel therapeutic composi 
tion for intranasal administration that contains loraZepam in 
a form that exhibits the same pharmacological activity as 
loraZepam compositions that are approved for oral, IM 
and/or IV administration, the intranasal composition being 
available for delivery in highly accurate and reproducible 
predetermined unit-doses leaving essentially no signi?cant 
quantity of the therapeutic composition after administration 
of the prescribed number of unit-doses. 
As used herein, the term “essentially no signi?cant quan 
tity of the therapeutic composition” means none, or a trace 
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amount, or an amount that is so small that it cannot be 
recovered for a subsequent unintended use or abuse after the 
prescribed use. 
As used herein, the term “spray” means the liquid com 
position expressed from the device under pressure in the 
form of an aerosol, a ?ne mist, liquid droplets, a ?ne stream, 
and combinations of tWo or more of the above forms. It Will 
be understood that the precise form of the composition is 
dependent upon the viscosity and other physical properties 
of the composition and the manner in Which the manual or 
other force is applied to the device to discharge the liquid 
composition. A heterogenous spray is acceptable so long as 
the sprayed volume is effectively adsorbed by the nasal 
mucosa. 
As used herein, “loraZepam” means loraZepam and its 
active pharmaceutically acceptable derivatives and metabo 
lites. 
SUMMARY OF THE INVENTION 
The improved loraZepam composition for intranasal spray 
administration is prepared by dissolving loraZepam in poly 
ethylene glycol having an average molecular Weight of 400, 
[“PEG 400” ] and diluting the solution With propylene 
glycol to a ?nal composition of about 20% PEG 400 and 
80% propylene glycol 2 by volume. 
The invention further comprehends the intranasal admin 
istration of the loraZepam composition in the form of a spray 
in a unit-dose of a predetermined therapeutic volume, Where 
substantially all of the predetermined volume of the com 
position is sprayed from delivery means Within a speci?ed 
narroW range of accuracy, While leaving essentially no 
signi?cant quantity of the therapeutic composition in the 
applicator from the unit-dose as administered. The dose is 
administered principally in the form of liquid droplets, that 
may be accompanied by a minor proportion of an atomiZed 
mist or an aerosol. Application to the nasal mucosa of a 
subject requiring treatment is consistent With the current 
therapeutic use of loraZepam for treatment of anxiety-related 
disorders, and especially useful When acute administration is 
indicated. Such indications include sedation of agitated 
and/or demented patients pre-operative surgical/dental seda 
tion and administration to children. 
The loraZepam compositions administered in accordance 
With the method and system of the invention exhibit sys 
temic pharmacological effects folloWing absorption from the 
nasal mucosa. As Will be shoWn beloW, the novel pharma 
ceutical composition provide the loraZepam in a form that is 
readily absorbable by the nasal mucosa Without damaging or 
irritating the mucosa, or producing an allergic, or other 
unacceptable reaction in the recipient. 
The loraZepam compounds for use in the practice of the 
invention comprise a pharmacologically acceptable carrier 
that can be nasally administered With safety over the entire 
reasonably foreseeable range of prescribed users of the 
composition. It has been found that the addition of Water to 
the composition reduces the stability of the loraZepam. It is 
therefore preferred that the liquid composition be non 
aqueous. Compatible organic solvents ar preferred. 
In one preferred embodiment, the loraZepam composition 
includes minor proportion of an arti?cial sWeetener. The 
purpose of the arti?cial sWeetener is to counteract or mask 
the otherWise bitter taste that the subject can experience if 
the composition reaches the taste buds. Flavor extracts can 
also be included in the composition, either in addition to or 
in place of an arti?cial sWeetener to mask the after taste of 
the loraZepam composition. The composition preferably has 
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a shelf life in the chosen delivery system of at least six 
months, and most preferably greater than tWo years. 
Optionally, the composition can include one or more pre 
servatives of the type approved for use in pharmaceutical 
compositions. The preservative is preferably an anti 
oxidant. One preservative that has been found particularly 
suitable is butylate hydroxytolune, Which can be added at the 
rate of 0.1 mg/mL. 
The loraZepam composition of the invention is also com 
patible With the delivery system. The loraZepam composi 
tions for use in the invention are formulated to deliver the 
dose Within the foreseeable temperature ranges of exposure, 
e.g., Without becoming too viscous to be administered in the 
proper form by the device, or crystalliZing at loWer tem 
peratures; and Without exceeding the internal pressure limits 
of the delivery system at higher temperatures. 
The predetermined therapeutic volume of the pharmaceu 
tical composition contained in the unit dose is delimited by 
several parameters, including the capability of the nasal 
passage to receive and absorb the volumetric quantity of 
spray; and the solubility of the particular loraZepam in the 
physiologically and pharmacologically acceptable carrier 
liquid at the concentration required to achieve the desired 
effect. The relative safety of administering a given prede 
termined quantity of loraZepam to classes of patients for 
anxiety-related disorders or for sedation, Whose body 
Weight, age, general health, use of other medications may 
vary Widely and can be determined by methods Well knoWn 
in the art. 
Dispensing devices meeting the above criteria and tech 
nical speci?cations have been provided in accordance With 
the invention by modifying commercially available devices, 
such as those sold by Pfeiffer of America of Princeton, N]. 
and Valois of America, Inc. of GreenWich, Conn. When 
modi?ed as described beloW, such devices have the capa 
bility of consistently delivering a predetermined volumetric 
amount of a liquid composition intranasally via a unit-dose 
dispenser that is manually operable by the patient requiring 
such intranasal drug administration. These manually oper 
able devices are designed for delivery of a single unit-dose, 
after Which there is essentially signi?cant quantity of the 
therapeutic composition remaining in the device. The device 
can thereafter be discarded Without concern that others may 
abuse the controlled substance. 
Commercial spray devices can be provided With enough 
pharmacologically active composition to administer one 
predetermined unit-dose or tWo unit-doses (“bi-dose”), each 
With a high degree of accuracy and reproducibility for the 
device and among a plurality of such commercially manu 
factured and ?lled devices. 
In accordance With the invention, the ori?ce of a com 
mercial spray applicator Was enlarged and the sWirl chamber 
is retained in order to produce a spray that is principally in 
the form of liquid droplets that coat the nares. A minor 
proportion of the product may be in the form of a mist or 
aerosol. The siZe of the ori?ce is optimiZed in relation to the 
viscosity of the loraZepam composition. 
Devices that are suitable for use in the practice of the 
invention are fabricated from a variety of polymeric 
materials, and can also include glass or polymer containers 
for the liquid loraZepam composition and metal components, 
preferably of stainless steel, that form elements of the 
delivery system. Such devices are compact, relatively inex 
pensive and can be discarded after the prescribed use. In a 
preferred embodiment, the container and its sealing means 
are steriliZable; most preferably, the entire device is con 
structed from materials that can be steriliZed. 
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The preparation of the loraZepam composition and its 
aseptic ?lling into containers and the assembly of the ?lled 
containers in the spray devices must be completed under 
aseptic conditions since the loraZepam cannot Withstand 
terminal steriliZation Without decomposition. Spray devices 
can be steriliZed before ?ling, along With the intended 
packaging, employing methods and technology that are Well 
knoWn in the art. 
BRIEF DESCRIPTION OF THE DRAWINGS 
The novel features and other advantages of the present 
invention, in addition to those mentioned above, Will 
become apparent to those skilled in the art from the folloW 
ing detailed description and in conjunction With the accom 
panying draWings, in Which: 
FIG. 1 is a graphic representation of the concentration of 
loraZepam in blood plasma versus time for IV, IM and IN 
doses; and 
FIG. 2 is a graphic representation of the data of FIG. 1 
over a longer time period. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT 
A suitable liquid composition for use in a spray device for 
intranasal administration includes a solvent in Which the 
desired concentration of loraZepam can be attained to pro 
vide the desired unit-dose in a total sprayed liquid volume 
that can be delivered by the device and accommodated and 
absorbed by the subject’s nasal mucosa. LoraZepam is 
insoluble in Water. A commercially available injectable 
composition approved by the FDA and sold by Wyeth 
Laboratories under the brand name Ativan®, includes 2 mg 
of loraZepam in 0.18 mL of polyethylene glycol 400 in 
propylene glycol With 2.0% benZyl alcohol as a preservative. 
This composition Was not acceptable for intranasal spray 
administration because benZyl alcohol is irritating to the 
mucosa. 
A suitable composition for use in the invention Was 
prepared as folloWs. 
LoraZepam Was formulated in a liquid composition for 
use in the practice of the invention. Since loraZepam is 
insoluble in Water, the loraZepam Was dissolved in polyeth 
ylene glycol having an average molecular Weight of about 
400 (“PEG400”), and the solution diluted With propylene 
glycol. In order to provide for shelf-life stability over a 
period of up to six-months under typical conditions, a 
preservative can be added. In a preferred embodiment, an 
arti?cial sWeeter is also dissolved in the composition. The 
?nal composition Was as folloWs: 
lorazepam 10.0 mg 
polyethylene glycol 400 0.18 mL 
propylene glycol 0.809 mL 
butylate hydroxytolune 0.1 mg 
saccharin (powder) 1.0 mg 
The loraZepam is preferably prepared in the form of a 
single or unit-dose nasal spray for intranasal administration 
by a precision dosage manually-activated pump. Each 1 ml 
of nasal spray solution is preferably formulated to contain 10 
mg loraZepam. In a preferred delivery system, each actua 
tion of the nasal spray pump delivers 0.1 ml of this 10 mg/ml 
hm solution constituting a 1 mg dose. A smaller dose of the 
loraZepam HCl can be administered to children. 
US 6,610,271 B2 
7 
As Will be understood by those familiar With the art, 
dosage forms at lower concentrations of loraZepam can be 
prepared for administration based upon the patient’s loWer 
body Weight, as in the case of children or adults of substan 
tially smaller siZe. The nasal spray solution has a pH in the 
range of from about 3 to about 7, With a pH of about 5 being 
preferred. 
The loraZepam composition Was placed in containers 
adapted for use With modi?ed Pfeiffer dispensers identi?ed 
by model/part numbers as 52020/BSK 7482. The intranasal 
applicators of the prior art are modi?ed by increasing the 
siZe of the discharge ori?ce in nose piece to about 0.07 mm 
from about 0.05 mm in diameter (Which is typical for an 
aqueous solution), i.e., a 40% increase in diameter. This 
increase is necessary to accommodate the higher viscosity of 
the composition of the invention. The sWirl chamber of the 
prior art precision spray dispenser can be retained. The 
applicator components are steriliZed by methods Well knoWn 
in the art. As Will be understood by those of ordinary skill 
in the art, other changes in the design and/or construction of 
the spray dispenser can be made to accommodate and 
discharge the more viscous composition of the invention. 
The loraZepam nasal spray applicators are preferably 
stored at temperatures in the range of 2°—8° C. (36°—48° and are protected from lig t to provide for maXimum shelf 
life. If the applicator body is not transparent, visual inspec 
tion of the drug product for signs of deterioration is not 
possible and attention to the eXpiration date and storage 
conditions is important. The optional inclusion of a preser 
vative Will serve to eXtend the shelf life, as Will storage 
under refrigeration. In the last case, the products and dis 
penser should be brought to room temperature before admin 
istration. Any expired product is discarded in the appropriate 
manner. 
A formulation of loraZepam for intranasal administration 
Was prepared as described above under aseptic conditions in 
the form of a liquid composition at a concentration of 1.0 mg 
of loraZepam in 0.1 mL. The composition Was used to ?ll the 
required number of single-dose, metered sprayers commer 
cially produced and sold by Pfeiffer of America, Inc., each 
of Which sprayers ?rst having been modi?ed as described 
above. The ?lling of the containers and their assembly is 
completed under aseptic conditions since the loraZepam 
composition cannot Withstand the heat of steriliZation. 
Each subject received a single spray in each nostril for a 
total of 2.0 mg. A 2.0 mg dose is preferred as being Within 
common, safe and labeled doses prescribed. Commercially 
available loraZepam Was purchased for IM and IV admin 
istration. The product Was Ativan® Injection for parental 
administration sold by Wyeth Laboratories, (a Wyeth-Ayerst 
Company.) Each mL of Ativan® Injection is formulated With 
2 mg of loraZepam in 0.18 mL PEG400 in propylene glycol 
With 2.0% benZyl alcohol as a preservative. The IV doses 
Were diluted according to the label instructions by adding 
one mL of Water. 
Each of the applicators Was Weighed prior to use and after 
use. Quali?ed medical personnel took the respective appli 
cators to subjects in a clinical setting; one dose Was admin 
istered up each nostril, after Which the applicator Was 
recovered for Weighing. Each subject used tWo Pfeiffer unit 
dose spray devices, both of Which Were discarded folloWing 
the post-use Weighing. The IV doses Were administered 
through antecubital veins on the arm opposite to the arm 
from Which samples Were taken, injecting the solution over 
about ?ve minutes. Syringes Were Weighed before and after 
administration. Further details of the protocol, and the 
10 
15 
20 
25 
35 
40 
45 
55 
60 
65 
8 
results of these studies of the methods and system of the 
invention and the comparative prior art method folloW. 
Unit-Dose: 
A statistical comparison of dose 1 and dose 2 for the 
Pfeiffer unit dose delivery system Was done using a paired 
t-test. Analysis of the data for normally functioning devices 
indicated that the difference betWeen the mean sprays of the 
tWo applications using the Pfeiffer device Was not statisti 
cally signi?cant. (This analysis eXcluded data from one of 
the devices that malfunctioned.) 
Investigational Methods 
A clinical study Was undertaken for the purposes of (1) to 
assessing the absolute bioavailability of loraZepam by com 
paring the pharmacokinetics of 2.0 mg loraZepam adminis 
tered by intranasal (IN) and intravenous (IV) routes; and (2) 
to compare pharmacokinetic parameters via IN administra 
tion to intramuscular (IM) and intravenous administration. 
This Was undertaken as a single-dose, open-label, three-Way 
crossover, randomiZed, pilot bioavailability study of 
loraZepam comparing intranasal administration in healthy 
human volunteers. 
TWelve healthy non-smoking subjects (siX male and siX 
female) betWeen the ages of 18 and 35 years Were initially 
selected for this inpatient study. One subject left the study 
and one subject received delayed doses. Study participants 
Were selected based on inclusion/exclusion criteria, history 
and physical eXam, laboratory tests, and other customary 
procedures. 
The subjects Were Within 120% of ideal body Weight and 
no history of allergies, acute or chronic nasal symptoms, 
signi?cant nasal surgery or abnormalities Were reported. 
Eleven of the tWelve subjects completed the study accord 
ing to the protocol. Each of the subjects received 3 doses of 
2 mg of loraZepam on three separate occasions. No clinically 
signi?cant protocol violations occurred during this study. 
The inclusion criteria mentioned abstinence from prescrip 
tion and non-prescription drugs prior to and during the study, 
and any medications taken in the 14 days before the study 
and during the study Were noted. Subjects abstained from 
alcoholic and caffeine-containing beverages for 48 hours 
before the dosing period and during the study. 
Clinical Trials 
Study Drug Formulation 
LoraZepam for intranasal administration Was supplied by 
the University of Kentucky College of Pharmacy. 
LoraZepam for intravenous administration (“IV”) Was sup 
plied as Ativan® 1 mg/mL for subjects 1, 3, 8, and 9 on the 
?rst day and for subjects 2, 4, 5, 6, and 7 on the second study 
day. LoraZepam for intramuscular administration (“IM”) 
Was supplied as Ativan® 2 mg/mL for subjects 2, 4, 5, 6 and 
7 on ?rst study day and for subjects 1, 3, 8 and 9 on the 
second study day. Free base content Was 1.77 mg or 88.7% 
of stated loraZepam strength (from molecular Weights: 
321.8—36.46=285.34, 285.34/321.8=88.7%) To summarize, 
the dosages for each of the three routes of administration 
Were as folloWs: 
Treatment A: 2.0 mg intravenous loraZepam; 
Treatment B: 2.0 mg intramuscular loraZepam; and 
Treatment C: 2.0 mg intranasal loraZepam solution 
Study Drug Administration 
Drug administration occurred at approximately 0800 
hours folloWing overnight fasting. Subjects Were alloWed up 
to 360 mL of juice or soft drink one hour before each dose, 
but Were not alloWed to eat for one hour after their dose. 
Safety Measures 
Weight, blood pressure, and pulse Were measured prior to 
dosing and at the end of the study. Blood pressure and pulse 
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rate Were measured With the subjects seated in an upright 
position before any corresponding blood sample Was col 
lected. Blood pressure and pulse rate Were measured and 
recorded on the same arm throughout the study at 0 (pre 
dose) and 30 minutes, 1, 2, 4, 8, and 16 hours. 
The three treatments Were separated by one-Week Wash 
out period. The subject (#02) Whose doses Were delayed 
received the ?nal dose Within one month of the ?rst dose, 
Was dosed With the other subjects during their ?rst and third 
periods and received the ?nal treatment tWo Weeks later. She 
Was dosed in the treatment order to Which she Was random 
iZed. 
Clinical Adverse Events 
Spontaneously reported adverse events Were recorded by 
the subjects throughout the study; adverse events Were also 
elicited by nondirected intervieWs. 
Sample Collection and Handling 
Blood samples for the three treatments Were collected 
from each subject according to the folloWing schedule: 0 
(pre-dose), 5, 15, 30 and 45 minutes, and 1, 2, 3, 4, 8, 12, 18, 
24 and 36 hours folloWing loraZepam administration. The 
beginning of the IV administration Was considered time 
Zero. After collection, the blood Was centrifuged in a refrig 
erated centrifuge at 4° C. to separate the plasma and the 
cells, and the plasma Was transferred to polypropylene tubes. 
The plasma Was stored at approximately —70° C. at the study 
site until shipped to an independent analytical service. The 
plasma Was maintained froZen during shipping and upon 
arrival at the remote analytical facility, the samples Were 
stored at approximately —20° C. until analyZed. 
Bioanalytical Methods 
LC/MS/MS Assay for LoraZepam 
The sample analysis using an LC/MS/MS assay Was 
performed by an independent service in accordance With 
established protocols. The analytic range for the loraZepam 
method Was 0.10 ng to 25.00 ng/mL using 1.0 mL of human 
plasma. Concentrations less than 1.10 ng/mL Were reported 
as beloW quantitation limit (BQL). Samples With concen 
trations greater than 25 ng/mL Were reanalyZed using a 
dilution so that the assayed concentration Was Within the 
range of 0.10 ng to 25.00 ng/mL. 
Pharmacokinetic Methods 
Plasma concentration versus time date for loraZepam Were 
analyZed using noncompartmental pharmacokinetic meth 
ods. Pharmacokinetic parameters Were determined using 
standard noncompartmental methods With log-linear least 
square regression analysis to determine the elimination rate 
constants (WinNonlin, Pharsight Corp., Palo Alto, Calif.). 
The areas under the concentration versus time curves from 
time Zero to in?nity (AUCO_OO) Were calculated by a com 
bination of the linear and logarithmic trapeZoidal rules, With 
extrapolation to in?nity by dividing the last measurable 
serum concentration by the elimination rate constant ()tz.) 
(Proost, 1985). Values for the maximum concentration 
(Cmwc) and time to Cmax (Tmax) Were determined by visual 
inspection of concentration versus time data for each sub 
ject. The elimination half-life Was determined from 0693/ 
K2. The absolute bioavailability for the IN and IM dosage 
forms, assuming equal 2 mg doses, Was determined by 
F=AUCIN)O_OO/AUCIV)O_OO for the IN dose and F= 
AUCIMD_OO/AUCW)O_Oo for the IM dose. Clearance (CL for IV 
and CL/F for IN and IM doses) Was determined by dividing 
the dose by AUCO_OO. Volume of distribution at steady state 
and for elimination (V55 and V2) Were determined by 
moment curves (Gibaldi and Perrier, 1982). 
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TABLE 1 
Mean (CV as a %) pharmacokinetic parameters following 
administration of 2 mg intravenous (IV infusion over 5 min), 
intranasal (IN) and intramuscular (IM) lorazepam doses in 
11 healthy volunteers. 
Parameter 2 mg IV 2 mg IM 2 mg IN 
Tmax (hrs*) 0.1 3.0 0.5 
(0.083 to 1.017) (0.5 to 8.017) (0.25 to 2) 
cmax (ng/mL) 47.57 (57.8) 22.58 (28.9) 21.38 (24.3) 
t1), (hr) 16.6 (27.3) 17.4 (38.1) 18.5 (28.3) 
AUc.H 386.8 (19.4) 372.8 (16.4) 288.0 (25.4) 
(ng - hr/mL) 
AUCM 500.8 (30.8) 506.2 (33.7) 393.5 (38.0) 
(ng - hr/mL) 
CL or CL/F (L/hr) 4.3 (27.0) 4.3 (28.5) 5.7 (31.8) 
vSS (L) 93.2 (11.9) _ _ 
vZ or VZ/F (L) 97.8 (15.2) 99.2 (10.8) 140.1 (16.8) 
F (% assume 100% 100.9 (10.2) 77.7 (11.1) 
*median and range given for Tmax 
Table 1 is a summary of pharmacokinetic data for the 
three doses. Absorption of loraZepam folloWing IN admin 
istration Was rapid as indicated by the fact that concentra 
tions Were detected in all subjects Within ?ve minutes after 
the IN administration. The median Tmax values Were 30 
minutes and three hours for the IN and IM doses, respec 
tively. On average, 0.1091 g (CV 5.6%, n=21) Was dis 
pensed from the individual spray pumps as determined by 
the difference in the pre- and post-Weights. (This data 
excludes one malfuctioning device of the 22 devices used in 
this study.) The mean plasma concentration versus time 
curve pro?les for the IV, IM and IN doses are shoWn in FIG. 
1. Plasma concentrations Were still detectable 36 hours after 
administration. 
FIGS. 1 and 2 are plots of the mean (n=11) plasma 
loraZepam concentration versus time graphs folloWing three 
treatments: (A) 2.0 mg loraZepam by ?ve minutes IV 
infusion, (B) 2.0 mg loraZepam IN dose and (C) 2.0 mg 
loraZepam IM dose. FIG. 1 shoWs the results over the period 
folloWing administration; FIG. 2 is the same data for the 36 
hours folloWing administration. 
Safety Results 
Results of the clinical measurement of vital signs and 
body Weight exams Were recorded and nasal exams Were 
performed. A revieW of this data failed to reveal any 
clinically signi?cant safety concerns. There Were no serious 
adverse events and no subjects Were discontinued due to 
adverse effects. Subjects commented that they experienced 
a mild bad taste immediately after the IN dose. Any safety 
concerns associated With IN are similar to those associated 
With IV administration. 
Detailed nasal examination demonstrated no pathology of 
the naso-pharynx after single administration of the 
loraZepam formulations. 
Pharmacokinetic Results 
The plasma loraZepam concentrations and actual collec 
tion times for each of the 11 subjects Was tabulated and 
plasma concentration-time curves for each of the 11 subjects 
Were prepared. The mean concentration-time curves of 
FIGS. 1 and 2 are representative for most subjects (mean 
data tabulation). FIG. 1 is a plot of the mean (n=11) 
loraZepam concentration versus time graphs folloWing IV, 
IM and IN doses of 2 mg loraZepam during the 4 hours after 
dose; FIG. 2 is the same data plotted for 36 hours after the 
dose. 
Noncompartmental pharmacokinetic analysis Was used to 
evaluate the plasma concentration versus time curves of 
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loraZepam following single 2.0 mg doses of loraZepam by 
intravenous (IV), intramuscular (IM), and intranasal (IN) 
routes. Individual plasma loraZepam concentration versus 
time pro?les for all subjects Were recorded; number of time 
points used to estimate the elimination rate constant Were 
also recorded; and a complete listing of individual and mean 
pharmacokinetic parameters for all 11 subjects Was 
recorded. Table 1 is a summary of the descriptive statistics 
for loraZepam pharmacokinetic parameters. 
Rapid absorption of loraZepam Was observed after the IV 
and IN doses. The Tmwc values Were approximately 9 and 18 
minutes, on average, for the IM and IN doses, respectively. 
The mean Tmax for the IV infusion Was not the ?rst blood 
sample after the end of the infusion for tWo reasons. The 
peak concentration after the IV dose in one subject Was not 
at the ?rst blood sample after the end of the IV infusion, but 
at the next time point. In the case of Subject 4, acquiring the 
blood sample immediately folloWing the IV infusion Was 
delayed resulting in the mean Tmax being affected. As 
expected, the loraZepam Cmax and AUCs Were signi?cantly 
higher after IM and IV administration compared to IN 
administration. Mean plasma half-lives and clearance after 
correcting for bioavailability, Were similar for all three 
treatments. 
The arithmetic mean value of absolute bioavailability of 
loraZepam (11 subjects) for the IN formulation is 78%. The 
plasma levels Were comparable to those of the IM dose. 
From the above, it Will be understood that a novel 
composition and method is provided for the safe and con 
trolled intra-nasal administration of precise doses of 
loraZepam in accordance With a medically prescribed regi 
men. 
What is claimed is: 
1. A pharmaceutical composition for intranasal adminis 
tration to a mammal that produces a sedative-anxiolytic 
physiological response in the mammal, the composition 
consisting essentially of: 
loraZepam; 
polyethylene glycol and propylene glycol as a solvent 
carrier for the loraZepam; Wherein the polyethylene 
glycol constitutes from about 15% to about 25% by 
volume and the propylene glycol constitutes from about 
75% to about 85% by volume of the composition; and 
a sWeetener, 
Wherein the composition forms a spray When discharged 
from a manually actuated spray device. 
2. The composition of claim 1, Wherein the polyethylene 
glycol has an average molecular Weight of about 400. 
3. The composition of claim 1, Wherein the polyethylene 
glycol constitutes about 20% by volume and the propylene 
glycol about 80% by volume of the composition. 
4. The composition of claim 3, Wherein the solvent-carrier 
is polyethylene glycol having an average molecular Weight 
of about 400. 
5. The composition of claim 3, Wherein the loraZepam is 
present in the composition at a concentration of 1.0 mg/0.1 
mL. 
6. A sprayable liquid pharmaceutical composition for 
intranasal administration in the form of at least one unit-dose 
to a mammal for the purpose of producing a sedative 
anxiolytic response in the mammal, the composition con 
sisting essentially of: 
loraZepam; 
polyethylene glycol and propylene glycol as a solvent for 
the loraZepam; Wherein the polyethylene glycol con 
stitutes from about 15% to about 25% by volume and 
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the propylene glycol constitutes from about 75% to 
about 85% by volume of the composition, a sWeetener, 
and 
a preservative, 
Wherein the loraZepam is present in the liquid composi 
tion at a concentration of about 1.0 mg/0.1 mL. 
7. The composition of claim 6, Wherein the polyethylene 
glycol has an average molecular Weight of about 400. 
8. The composition of claim 7, Wherein the ratio of 
polyethylene glycol to propylene glycol is about four-to 
one. 
9. The composition of claim 7, Wherein the solvent 
constitutes about 80% by volume and the propylene glycol 
about 18% by volume. 
10. The composition of claim 6, Wherein the sWeetener is 
selected from the group consisting of saccharin and aspar 
tame. 
11. The composition of claim 10, Wherein the sWeetener 
is saccharin. 
12. The composition of claim 6, Wherein the preservative 
is butylated hydroxytoluene. 
13. A method of treating a mammal exhibiting symptoms 
of anxiety-related disorders, said mammal requiring 
treatment, the method comprising the steps of: 
a. providing an intranasal spray delivery device; 
b. ?lling the delivery device With a sprayable liquid 
composition, the liquid composition consisting essen 
tially of: 
loraZepam, polyethylene glycol and propylene glycol 
as a solvent-carrier for the loraZepam; Wherein the 
polyethylene glycol constitutes from about 15% to 
about 25% by volume and the propylene glycol 
constitutes from about 75% to about 85% by volume 
of the composition, a sWeetener, and 
c. administering a predetermined measured dose of the 
liquid loraZepam containing composition intranasally 
to the mammal requiring treatment by spraying the 
liquid composition droplets from the delivery device 
into at least one of the mammal’s nostrils. 
14. The method of claim 13, Wherein the dose is admin 
istered by manually activating the delivery device. 
15. The method of claim 13, Wherein the predetermined 
dose is administered by spraying the loraZepam-containing 
composition ?rst in one nostril and then in the other. 
16. The method of claim 13, Wherein the mammal is an 
adult human and the predetermined dose is tWo Mg of 
loraZepam. 
17. The method of claim 13, Wherein the sprayable liquid 
composition is prepared by dissolving loraZepam in the 
solvent carrier and adding the loraZepam in the solvent 
carrier to the delivery device under aseptic conditions. 
18. The method of claim 13 Which includes the further 
step of steriliZing the delivery device before addition of the 
liquid composition. 
19. A pharmaceutical composition for intranasal admin 
istration consisting essentially of: 
loraZepam; 
polyethylene glycol and propylene glycol; Wherein the 
polyethylene glycol constitutes from about 15% to 
about 25% by volume and the propylene glycol con 
stitutes from about 75 % to about 85 % by volume of the 
composition; 
and a sWeetener. 
20. A composition according to claim 19, Wherein the 
polyethylene glycol has an average molecular Weight of 
about 400. 
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21. A composition according to claim 19, wherein the 
polyethylene glycol constitutes about 20% by volume and 
the propylene glycol about 80% by volume of the compo 
sition. 
22. A composition according to claim 19, Wherein the 
loraZepam is present in the composition at a concentration of 
1.0 mg/0.1 ml. 
23. The composition of claim 19, Wherein the sWeetener 
is saccharin, aspartame or combination thereof. 
24. A pharmaceutical composition for intranasal admin 
istration consisting essentially of: 
loraZepam; 
polyethylene glycol and propylene glycol; Wherein the 
polyethylene glycol constitutes from about 15% to 
about 25% by volume and the propylene glycol con 
stitutes from about 75% to about 85% by volume of the 
composition; 
a sWeetener, and a preservative. 
25. A composition according to claim 24, Wherein the 
sWeetener is saccharin, aspartame or combination thereof. 
26. A composition according to claim 24, Wherein the 
preservative is butylated hydroXytoluene. 
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27. A pharmaceutical composition for intranasal admin 
istration consisting essentially of: 
loraZepam 10.0 mg; 
polyethylene glycol 400 0.18 mL; 
propylene glycol 0.09 mL; 
butylated hydroXytoluene 0.1 mg; and 
saccharin 1.0 mg. 
28. Amethod of treating a mammal suffering from anxiety 
comprising intranasally administering a pharmaceutical 
composition consisting essentially of: 
loraZepam; 
polyethylene glycol and propylene glycol; Wherein the 
polyethylene glycol constitutes from about 15% to 
about 25% by volume and the propylene glycol con 
stitutes from about 75% to about 85% by volume of the 
composition; 
a sWeetener; and a preservative, Wherein the composition 
achieves a plasma loraZepam Cmwc of at least 21 ng/ml 
When administered intranasally. 
* * * * * 
